Who owns CNAT - CONATUS PHARMACEUTICALS INC - COM based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CONATUS PHARMACEUTICALS INC - COM (CNAT) Institutional Ownership

Q: What is CUSIP 20600T108?

CUSIP 20600T108 is the security identifier used in SEC filing datasets for CNAT - CONATUS PHARMACEUTICALS INC - COM.

CUSIP: 20600T108

13F Institutional Holders and Ownership History from Q1 2014 to Q2 2020

Type / Class: Equity / COM
Symbol: CNAT

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP 20600T108?
CUSIP 20600T108 identifies CNAT - CONATUS PHARMACEUTICALS INC - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 20600T108:

Q2 2020 (0 holders) Q1 2020 (24 holders) Q4 2019 (26 holders) Q3 2019 (23 holders) Q2 2019 (33 holders) Q1 2019 (42 holders) Q4 2018 (50 holders) Q3 2018 (53 holders) Q2 2018 (59 holders) Q1 2018 (72 holders)

Institutional Holders of CONATUS PHARMACEUTICALS INC - COM (CNAT) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2020 Q2	0	$0	-$1,562,000				0
2020 Q1	5,023,107	$1,558,003	+$143,611			$0.31	24
2019 Q4	4,562,004	$1,822,004	+$113,370	$0	$0	$0.40	26
2019 Q3	4,223,013	$1,328,163	-$295,384	$10,000	$16,000	$0.31	23
2019 Q2	5,285,551	$1,376,134	-$3,320,148	$16,000	$34,000	$0.26	33
2019 Q1	8,468,149	$9,146,490	-$544,672	$170,000	$1,614,000	$1.08	42
2018 Q4	8,284,431	$14,341,785	-$8,018,114	$871,000	$1,847,000	$1.73	50
2018 Q3	9,655,412	$55,991,633	-$5,818,024	$985,000	$2,934,000	$5.80	53
2018 Q2	10,800,924	$46,229,779	-$8,322,659	$225,000	$858,000	$4.28	59
2018 Q1	12,206,413	$71,644,242	+$2,260,458	$270,000	$493,000	$5.87	72
2017 Q4	11,881,672	$54,896,960	+$2,888,624	$169,000	$442,000	$4.62	70
2017 Q3	11,078,636	$60,820,724	+$6,229,636	$463,000	$569,000	$5.49	78
2017 Q2	9,980,329	$57,482,688	+$26,271,514	$829,000	$1,167,000	$5.76	70
2017 Q1	5,418,060	$31,258,126	+$6,528,127	$841,000	$1,280,000	$5.77	42
2016 Q4	4,454,398	$23,475,000	+$2,670,603	$506,000	$925,000	$5.27	41
2016 Q3	4,160,585	$8,313,000	-$1,807,756	$42,000	$91,400	$2.00	38
2016 Q2	5,033,149	$10,359,000	+$109,499	$76,000	$120,000	$2.06	35
2016 Q1	4,978,905	$10,655,000	-$2,594,796	$36,000	$39,000	$2.14	32
2015 Q4	5,825,806	$16,762,000	-$5,087,774	$268,000	$96,000	$2.88	40
2015 Q3	6,935,905	$30,861,000	+$1,097,246	$426,000	$260,000	$4.45	37
2015 Q2	6,652,546	$34,258,000	+$12,459,029	$461,000	$737,000	$5.15	33
2015 Q1	3,971,056	$19,618,488	+$2,783,764	$1,188,000	$764,000	$7.12	32
2014 Q4	3,585,558	$25,076,000	-$2,294,850	$803,000	$695,000	$7.00	36
2014 Q3	3,933,518	$24,058,000	-$8,762,337	$768,000	$535,000	$6.12	33
2014 Q2	5,007,134	$45,610,000	-$11,084,969	$139,000	$426,000	$9.11	37
2014 Q1	6,394,464	$52,023,183	+$4,109,127			$8.14	46